Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Fabrinet — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.03 (market cap $3.94B), while Fabrinet trades at $380.8 (market cap $15.33B). The key difference: Fabrinet is far larger — about 3.9× Edgewise Therapeutics Inc. Common Stock's market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Fabrinet for 31 Days on average.
| EWTX | FN | |
|---|---|---|
Market Cap | $3.94B | $15.33B |
Volume | 810,104 | 1,120,187 |
Sector | Health | Technology |
52-Week High | $48.35 | $746.47 |
52-Week Low | $14.89 | $374.91 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $3.48B | $14.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Fabrinet (FN) trades at $427.82, down 6.26% in the last session amid broader market volatility. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust 45% revenue growth in Q4 2026. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages, while support levels cluster around $407-$441. The company benefits from surging AI data center demand and capacity expansion initiatives.
Fabrinet's outlook remains positive driven by AI infrastructure growth, though risks include customer concentration and margin pressure. Analysts project 64% upside to the $769.50 consensus target with unanimous bullish sentiment (18 buys, 0 sells). The stock offers exposure to high-growth optical manufacturing but faces execution risks in capital expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
